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Haematopoietic stem cell transplantation has been proposed as treatment for mitochondrial neurogastrointestinal encephalomyo-
pathy, a rare fatal autosomal recessive disease due to TYMP mutations that result in thymidine phosphorylase deﬁciency. We
conducted a retrospective analysis of all known patients suffering from mitochondrial neurogastrointestinal encephalomyopathy
who underwent allogeneic haematopoietic stem cell transplantation between 2005 and 2011. Twenty-four patients, 11 males and
13 females, median age 25 years (range 10–41 years) treated with haematopoietic stem cell transplantation from related (n = 9) or
unrelated donors (n = 15) in 15 institutions worldwide were analysed for outcome and its associated factors. Overall, 9 of 24
patients (37.5%) were alive at last follow-up with a median follow-up of these surviving patients of 1430 days. Deaths were
attributed to transplant in nine (including two after a second transplant due to graft failure), and to mitochondrial neurogas-
trointestinal encephalomyopathy in six patients. Thymidine phosphorylase activity rose from undetectable to normal levels (median
697 nmol/h/mg protein, range 262–1285) in all survivors. Seven patients (29%) who were engrafted and living more than 2 years
after transplantation, showed improvement of body mass index, gastrointestinal manifestations, and peripheral neuropathy.
Univariate statistical analysis demonstrated that survival was associated with two deﬁned pre-transplant characteristics: human
leukocyte antigen match (10/10 versus 510/10) and disease characteristics (liver disease, history of gastrointestinal pseudo-
obstruction or both). Allogeneic haematopoietic stem cell transplantation can restore thymidine phosphorylase enzyme function
in patients with mitochondrial neurogastrointestinal encephalomyopathy and improve clinical manifestations of mitochondrial
neurogastrointestinal encephalomyopathy in the long term. Allogeneic haematopoietic stem cell transplantation should be con-
sidered for selected patients with an optimal donor.
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Introduction
Mitochondrial neurogastrointestinal encephalomyopathy
(MNGIE) is an autosomal recessive multisystem disorder
due to TYMP mutations, which leads to premature death.
TYMP mutations cause loss of thymidine phosphorylase
(TP) activity (Hirano et al., 1994; Nishino et al., 1999),
resulting in more than a 50-fold increase in levels of thy-
midine and deoxyuridine in plasma and tissues (Spinazzola
et al., 2002; Valentino et al., 2007). As a consequence of
this accumulation of nucleosides, intramitochondrial deox-
ynucleotide pools are unbalanced, which in turn impair
mitochondrial DNA (mtDNA) replication leading to accu-
mulation of site-speciﬁc point mutations, multiple deletions,
and depletion of mtDNA (Hirano et al., 1994;
Papadimitriou et al., 1998; Nishigaki et al., 2003, 2004).
As a result of the mtDNA instability, patients develop
progressive mitochondrial oxidative phosphorylation
(OXPHOS) dysfunction with gastrointestinal dysmotility,
cachexia, peripheral neuropathy, skeletal myopathy,
ophthalmoparesis and ptosis over the course of 2–4 decades
(Papadimitriou et al., 1998; Garone et al., 2011). MRI of
the brain reveals leukoencephalopathy; however, cognitive
function is generally unimpaired. Diagnosis is usually made
in the second or third decade of life although onset of ﬁrst
clinical signs is frequently described during childhood or
adolescence. The disease is relentlessly progressive and
causes death primarily due to cachexia and infections,
with a median life expectancy of 37 years (Garone et al.,
2011).
To date, no widely available effective disease-modifying
treatment is available for MNGIE. Attempts to reduce toxic
nucleoside levels with dialysis failed because of rapid
reaccumulation of thymidine (Spinazzola et al., 2002; la
Marca et al., 2006; Yavuz et al., 2007). Erythrocyte-
encapsulated TP showed preliminary hints of efﬁcacy in
one patient but must be infused multiple times per year
(Bax et al., 2013). In a proof-of-concept trial, transfusions
with platelets, which contain abundant TP, produced tran-
sient reduction of nucleoside levels (Lara et al., 2006). This
approach is not feasible as long-term therapy, but has sti-
mulated the concept of enduring replacement of TP by
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allogeneic haematopoietic stem cell transplantation (HSCT)
as donor-derived leucocytes and platelets are rich in TP
(Hirano et al., 2006; Halter et al., 2011). Because nucleo-
sides diffuse between extra-and intracellular compartments,
TP from normal donor cells can clear thymidine and deox-
yuridine from plasma and presumably also from tissues of
MNGIE patients. Biochemical success of this concept has
been reported (Hirano et al., 2006), however, clinical bene-
ﬁt has not yet been demonstrated.
Materials and methods
Study design
This retrospective study analysed data of all known MNGIE
patients worldwide who started conditioning therapy for allo-
geneic HSCT, starting from the ﬁrst patients who underwent
HSCT in Haifa, Israel in July 2005 and in New York, USA in
August 2005 (Hirano et al., 2006). MNGIE is a very rare
disease with only a few diagnostic laboratories performing
metabolic and genetic analyses, hence virtually all patients
with this disease have been brought to the attention of two
of the co-authors (M.H., R.M.) who established a robust net-
work for patient identiﬁcation. Involved clinical teams were
contacted and data were systematically collected by a question-
naire and personal contacts. Data collection included
Karnofsky performance score, clinical general medical, neuro-
logical and ophthalmological exams; blood tests (complete
blood counts, and routine blood chemistry); imaging studies
(brain MRI, upper and lower gastrointestinal series, abdominal
ultrasound); electrophysiological assessments (nerve conduc-
tion studies, electromyography); disease-speciﬁc biochemical
studies (TP activity in buffy coat, thymidine and deoxyuridine
plasma levels) and genetic testing (TYMP and mtDNA muta-
tion screening). Data collection on HSCT included pre-
transplant health status, conditioning, graft-versus-host disease
(GvHD) prophylaxis and treatment, donor type, stem cell
source, donor cell chimerism, post-transplant course and sur-
vival. The last follow-up evaluations were performed in June
2012, and the survival was last updated in December 2013.
Statistics
Survival was censored at the time of last follow-up (December
2013), death or time of second transplantation. Descriptive
statistics were calculated for demographic, MNGIE-related
and HSCT-related characteristics. The overall survival was
estimated by the Kaplan-Meier method. Univariate analysis
of the association between age, gender, body mass index, par-
enteral nutrition at the time of HSCT, history of intestinal
pseudo-obstruction or perforation, liver disease (deﬁned as
transaminases more than twice the upper limit of normal or
histological abnormality), donor type, human leukocyte anti-
gen (HLA)-match, stem cell source, intensity of conditioning
(intensive versus reduced intensity, classiﬁed according to pub-
lished working deﬁnition) (Bacigalupo et al., 2009) and overall
survival was conducted. A P-value 40.05 was considered sig-
niﬁcant. Due to the limited number of patients we were unable
to complete multivariate analysis. Analyses were performed by
IBM SPSS Statistics, Version 19 (SPSS, Inc. IBM copyright
1989, 2010).
Results
Patient population
A total of 26 patients (13 male, 13 female) with MNGIE
were reported to have started conditioning treatment for
HSCT (Fig. 1); this includes the seven patients who have
already been reported (Hirano et al., 2006; Bakker et al.,
2010; Filosto et al., 2012; Sicurelli et al., 2012; Finkenstedt
et al., 2013). Baseline clinical and genetic characteristics are
presented in Table 1 and Supplementary Table 1.
Two of the initial 26 patients did not proceed to HSCT.
One died before transplantation in septic shock with acute
respiratory distress syndrome (ARDS) due to infection with
Acinetobacter baumanii of unknown origin (Bakker et al.,
2010). The other developed acute cardiogenic shock after
administration of alemtuzumab with subsequent cardiopul-
monary failure. The patient recovered fully but died 5 years
later due to disease progression. Both of these patients had
a history of pseudo-obstruction and signs of liver disease.
The ﬁrst suffered also from two episodes of intestinal per-
foration. This report focuses on the 24 patients who under-
went HSCT.
Median age at diagnosis of MNGIE was 21 years (range
9.5–34) but clinical onset was at a median age of 15.5
years (range 4–30). Diagnosis of MNGIE was conﬁrmed
in all patients by biochemical testing, identiﬁcation of
TYMP mutations or both (Table 1) (Hirano et al., 2006;
Schu¨pbach et al., 2007; Poulton et al., 2009; Bakker et al.,
2010). TYMP mutations resulted in drastically reduced TP
activity (n = 20, median value below detection limit, range
0–28 nmol/h/mg protein, normal 634  217) and detectable
pyrimidine nucleosides in plasma (n = 15, median level of
thymidine 9.6 mmol/l, range 4.1–96.2, median level of deox-
yuridine 13.6 mmol/l, range 7.7–305.3; normal thymidine
and deoxyuridine 50.05). Blood lactate levels were ele-
vated during fasting in 9 of 11 patients tested (median
3mM, range 2.1–6.1; normal 0.5–2.2). Increased CSF pro-
tein levels (median 82mg/dl, range 53–329; normal 545)
were observed in all eight patients who underwent lumbar
puncture. Thymidine and deoxyuridine levels in CSF were
measured in only two patients before transplantation. In
both, levels of these nucleosides were similar to plasma
levels, conﬁrming previous ﬁndings that thymidine and
deoxyuridine cross the blood–brain barrier (Thomas ne´e
Williams et al., 1996). Brain MRI scans were performed
in 19 patients and revealed symmetric leukoencephalopathy
in all but one (95%). Common clinical manifestations
included cachexia (100%), gastrointestinal dysmotility
[gastrointestinal motility studies were abnormal in 11 of
14 patients tested (79%) with delayed gastric emptying,
intestinal dysmotility or both], and ophthalmoparesis in
68%. Electromyography was performed in 14 patients
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and showed pathologic neurogenic, myopathic, or both
patterns in nine (64%) and was normal in ﬁve patients.
Nerve conduction studies were markedly abnormal in all
18 patients examined (100%) and revealed predominantly
demyelinating sensorimotor peripheral neuropathy
(Supplementary Table 1). In 10 patients, consanguinity of
their parents was noted.
Pre-transplant characteristics
Median age at transplantation was 25 years (range 10–41).
All patients were cachectic with a median body mass index
of 13.5 kg/m2 (range 10–19). Before HSCT, 12 patients
were receiving parenteral nutrition. Median Karnofsky per-
formance score was 70% (range 30–90) indicating the
patients’ frail status.
Twenty-four patients underwent a ﬁrst HSCT. A variety
of different regimens for conditioning and graft-versus-host
disease prophylaxis were used in the ﬁrst 12 patients with a
preference for reduced intensity conditioning regimens
(Table 2 and Supplementary Table 2). After a ﬁrst consen-
sus meeting in late 2008 (Halter et al., 2011), a more
homogenous transplant strategy has been followed.
Fludarabin/busulfan (n = 17) in combination with anti-T
cell antibodies (n = 8) was the most frequent conditioning
regimen for ﬁrst HSCT. Cyclophosphamide was used in
eight patients; all but two before the consensus recom-
mendations. More donors were unrelated (n = 15; 63%)
than related (n = 9; 37%). Sixteen (67%) were either
HLA-identical related donors (n = 9) or at least 10/10-
HLA-matched unrelated donors (n = 7). Eight donors
(33%) had at least one or more HLA-mismatches, includ-
ing all ﬁve patients who underwent cord blood transplant-
ation. Bone marrow was the preferred source of stem cells
for ﬁrst HSCT in half of the patients (n = 13, 54%), fol-
lowed by peripheral blood stem cells (n = 6; 25%) and cord
blood (n = 5; 21%).
Transplant outcome
Neutrophils (polymorphonuclear leucocytes; PMN)
engrafted in 20/24 patients (83%) after a median of
16 days (range 8–26 days; in one patient PMN count
was never 5500/ml). One died before engraftment (21
days after transplant). Primary graft failure occurred in
three patients, two of whom received a second HSCT
with more intensive conditioning regimens 331 and 247
days after ﬁrst transplants. Although both engrafted suc-
cessfully, they died from transplant-related complications.
The third patient died from progressive manifestations of
MNGIE. In two other patients, late graft failure was
observed 4 and 12 months after transplantation. One
died from progressive disease, the other underwent a
second HSCT from the same donor 473 days after ﬁrst
transplantation and is still alive with established full
donor chimerism. All other patients had stable graft func-
tion after ﬁrst transplantation until last follow-up.
Overall, nine patients were alive at last follow-up
(37.5%) with a median follow-up of 1430 days (range
832–3084), all with stable engraftment (Fig. 2A). Fifteen
patients have died. Seven patients died because of
transplant-related causes at a median of 105 days (range
18–453: graft-versus-host disease in four, toxicity in two
and infection in one). Two more patients died from trans-
plant-related toxicity after second HSCT. In addition, six
patients died because of MNGIE-related causes—mainly
gastrointestinal complications—after a median of 198
days (84–1196 days). Pre-existing MNGIE-associated intes-
tinal pathology likely contributed signiﬁcantly to death
during the ﬁrst 6 months post-transplant in three of nine
patients and was the main cause of death in four of six
patients dying more than 6 months after ﬁrst transplant-
ation. By univariate analysis, HLA-match (10/10 versus
510/10) and the combination of indicators of disease
burden (history of pseudo-obstruction, liver disease or
both) were associated with overall survival (Fig. 2B and
Figure 1 Number of patients treated and outcome.
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C, and Supplementary Fig. 1). Although reduced intensity
conditioning initially resulted in better survival (Fig. 2D)
this advantage disappeared due to graft failure necessitating
second HSCTs that were associated with a high transplant-
related mortality (Fig. 2E).
Follow-up of MNGIE disease
manifestations
After HSCT, buffy coat TP activity became detectable with
engraftment and showed a rapid increase thereafter to
normal levels, except in one patient with a donor who
carried a TYMP mutation (median buffy coat TP activity
697 nmol/h/mg protein, range 262–1285; Fig. 3A). In par-
allel, normalization of plasma thymidine (median
50.05mM/l, range 0–0.8) and deoxyuridine levels
(median 50.05 mM/l, range 0–1.3) was observed, except
in Patient 4 (0.8 mM/l) with ongoing late graft failure
(Fig. 3B). Fasting plasma lactate levels were measured
before and after transplantation in ﬁve patients with a
follow-up of more than 2 years. Median lactate decreased
from 2.3mM (range 2.1–3.5) to 1.7mM (range 1.5–1.9)
after transplantation, suggesting improvement of mitochon-
drial respiratory chain function.
Slight clinically detectable improvements were observed
as early as 6 months in some patients, but varied widely.
Therefore, further analysis is focused on the seven patients
that have survived for more than 2 years after ﬁrst HSCT
after a median follow-up of 53 months (range 27–85
months). Five patients have discontinued immunosuppres-
sive treatment, and one is tapering immune-suppressants.
Patient 6 died after more than 3 years post-transplantation.
Long-term results of patients surviving at least 2 years after
HSCT are shown in Fig. 3C–F.
Weight and gastrointestinal parameters
All patients were cachectic before transplantation. Patients
lost weight during and in the initial period after HSCT.
Despite high caloric food intake, patients experienced
weight gain only after a year post-transplant. At last
follow-up, median weight increase is 2.5 kg (range
0.7–18) (Fig. 3A). Diarrhoea resolved in ﬁve patients who
also became free of abdominal pain. Diarrhoea improved in
one patient and remained unchanged in another; in both,
abdominal pain persisted. In three patients, parenteral nu-
trition was initiated after HSCT because of weight loss
during post-transplant phase, but was later stopped in
two; the third patient continues nocturnal parenteral nutri-
tion to complement oral intake. Two further patients con-
tinue parenteral nutrition, which had already been initiated
before transplantation; two never had parenteral nutrition.
Figure 2 Overall survival. (A) Overall survival of the whole cohort with a median overall survival of 453 days. (B–E) Univariate analysis for
factors associated with overall survival: HLA-match (B), history of gastrointestinal pseudo-obstruction and/or liver disease (C), intensity of
conditioning regimen (D) and overall survival depending on intensity of conditioning regimen if outcome after second HSCT is included into
survival analysis (E). RIC = reduced-intensity conditioning; IC = intensive, myeloablative conditioning.
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Neurological findings
Peripheral neuropathy improved in affected patients with
improved sensation (3/3) and restoration of tendon reﬂexes
(4/5 with follow-up more than 3 years), starting as early as
6 months after transplantation and further improvements
were observed in follow-up Years 2–4. One patient remains
areﬂexic more than 5 years post-transplant. Three patients
with glove and stocking-sensory deﬁcits pre-transplant had
partial improvement.
Five of the seven patients had ophthalmoparesis
pre-transplant. This remained static for more than 1 year;
however, eye movements slightly improved in the four in-
dividuals with more than 2 years follow-up.
Muscle atrophy was present in six of seven patients and
persisted during long-term follow-up. After transient wor-
sening of weakness following HSCT, muscle strength
improved in all seven patients. Gait remained normal in
four and improved in two. One patient remained unable
to walk as prior to the HSCT. Cognition remained un-
affected in all seven patients. Lumbar punctures were not
performed after transplantation in any patient.
MRI of the brain
Leukoencephalopathy was present in all seven patients
before HSCT. Although no formal volumetric analysis
was performed, radiologists reported a slight increase of
hyperintense lesions in three of them after 6 to 12
months but without clinical correlates. After a follow-up
of more than 4 years, leukoencephalopathy improved in
one patient and remained stable in ﬁve.
Electrophysiological studies
Improvement or at least stabilization of F-wave latencies
and sensory and motor nerve conduction velocities was
observed in all ﬁve patients assessed post-transplant.
Results of measurements of the ulnar nerve are shown in
Fig. 3D–F and Supplementary Table 3. These observations
were conﬁrmed by measurements of the median and pero-
neal nerve (data not shown). Compound muscle potentials
also increased in all nerves measured in ﬁve patients as-
sessed (Fig. 3F and Supplementary Table 3). Due to the
small number of patients, no statistical analysis was per-
formed but with increasing follow-up there seems to be a
trend towards improvement of nerve conduction.
Discussion
In this retrospective study, we describe the experience of
allogeneic HSCT in MNGIE patients. Despite the limita-
tions of a heterogeneous cohort of patients transplanted
under diverse protocols, this analysis produces several im-
portant conclusions. Firstly, we conﬁrm in a large group of
Figure 3 Metabolic and clinical MNGIE manifestations pre- and post-transplant. (A) TP activity in buffy coat before and after HSCT
(paired t-test, two tailed: P5 0.0001). (B) Thymidine levels in plasma before and after HSCT (P5 0.0001). (C–F) Results of patients with follow-
up 42 years. Shapes of symbols identify individual patients. Due to small patient numbers no statistical analysis was performed but a trend
towards improvements of body mass index (BMI) and nerve conduction studies can be observed in long-term follow-up as exemplified by: (C)
change of body mass index 2, 3, and 4 years after transplantation; (D) F-wave latency of ulnar nerve; (E) distal motor conduction velocity of ulnar
nerve; and (F) ulnar compound muscle potential (mV).
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patients that successful engraftment after allogeneic HSCT
leads to a rapid normalization of TP enzyme activity and
elimination of toxic metabolites but clinical improvement
takes a much longer time and residual disease manifest-
ations persist for years after HSCT. This is probably be-
cause the neurological and gastrointestinal features are due
to multiple deletions, depletion, and point mutations of
mtDNA that were acquired over many years of exposure
to toxic levels of thymidine and deoxyuridine, causing pro-
gressive loss of mitochondrial function and cells with irre-
versible tissue destruction. Only after normalization of
intra-mitochondrial deoxynucleotide pools, further
damage to mtDNA may be prevented and improvements
of the mtDNA depletion (but not deletions or point muta-
tions) are likely to occur. Direct assessment of mtDNA in
affected tissues was not performed because correlating the
amounts of mtDNA deletions, depletion, and point muta-
tions with clinical signs and symptoms would require inva-
sive biopsies of all affected tissues (e.g. peripheral nerves,
muscle, brain, and gastrointestinal tract) in patients who
are already medically compromised. Furthermore, because
there is regional variability of the pathology in affected
tissues, sampling a severely or mildly affected area might
show greater or lesser pathology than is present overall in
the affected organ or peripheral nerves.
We have been able to demonstrate that the clinical mani-
festations of MNGIE improved signiﬁcantly over time, even
in patients with very severe disease manifestations. None of
the patients surviving more than 1 year showed progression
of MNGIE-related manifestations while objective improve-
ments of clinical manifestations were observed only after
2 years. Organ recovery may continue over several more
years, but the extent of restoration of organ function
remains uncertain. Recovery of the gastrointestinal tract
seems to be slow and at the time of analysis, incomplete.
Weight gain occurred only slowly, even in patients who
resumed oral feeding and were able to ingest high caloric
nutrition. Complementary parenteral nutrition, e.g. over-
night feeding, can support nutritional intake and beneﬁts
of prolonged use should be carefully weighed against risks
such as infection or catheter-related thrombosis. While leu-
koencephalopathy is typically asymptomatic, neurological
problems in MNGIE are primarily due to peripheral neur-
opathy. Poor recovery of the peripheral neuropathy is
probably due to irreversible chronic axonal damage.
Nevertheless, because the neuropathy is primarily demyeli-
nating, partial improvements were evident in our patients.
Due to the frailty of the patients, transplant- or MNGIE-
related complications remained persistent threats that can
trigger further declines in performance score and organ
function.
Mortality in this series of 24 patients was substantial.
Both transplant-related causes as well as pre-existing
MNGIE-related comorbidities contributed to this unfavour-
able overall outcome. This suggests that risks and beneﬁts
have to be carefully balanced. Of note, no patient above
the age of 30 and no patients with a less than 10/10 HLA-
antigen matched donor survived. The presence of liver dis-
ease and a history of gastrointestinal pseudo-obstruction
can be used as markers for disease stage in a similar
manner as conventional co-morbidity risk scores (Sorror
et al., 2007).
Patients with MNGIE tolerate drugs differently in part
due to their poor physical condition, but also due to the
relative reduction of mitochondria. This issue was appre-
ciated at an early stage by some groups and resulted in a
consensus statement for future transplants performed in
patients with MNGIE (Halter et al., 2011). The small
number of patients precludes a deﬁnitive statement about
the value of these recommendations.
Reduction of transplant-related toxicity is important as
well as a reduction of the high rate of primary graft failure
observed. Toxicity can be reduced by limiting the number
of pre-transplant risk factors, risk of rejection can be low-
ered by careful selection of HLA-matched donors, an ad-
equate number of cells in the graft (Halter et al., 2011) and
strict monitoring of chimerism to detect graft-failure early
and guide therapeutic approaches to prevent graft loss. Of
note, the ﬁve patients who underwent unrelated cord blood
transplantation died of transplant-related causes. None of
them had an HLA-identical transplant, suggesting that
other than well-matched unrelated cord blood cannot yet
be considered routinely for HSCT in MNGIE as it is also
true for non-malignant haematological disorders
(Gluckman et al., 2007; Bizzetto et al., 2011; Boelens
et al., 2013). To date, it remains a challenge to determine
the optimal time point for HSCT. A failed early transplant-
ation could deprive patients of years of good quality of life;
HSCT attempted too late may result in an even higher
mortality risk and leave the patient with irreversible neuro-
logical and gastrointestinal deﬁcits. Despite these complicat-
ing factors, some guidance for future transplantation in
MNGIE can be derived from the experience gained to
date. First, when detectable, TP level did not correlate
with clinical outcome, i.e. partial restoration was adequate.
Second, because the majority of post-transplant complica-
tions have been related to pre-transplant risk factors,
immunosuppressive treatment and gastrointestinal prob-
lems due to MNGIE, our data suggest that HSCT should
be considered, preferably in younger patients before severe
gastrointestinal dysmotility and liver disease develop if
an ideal donor can be identiﬁed. Similarly, HSCT should
not be recommended for patients with advanced disease
and lacking a donor with at least a 10/10 HLA antigen
match.
In conclusion, allogeneic HSCT can alter the natural
course of MNGIE, an otherwise debilitating and inevitably
fatal disease. In view of the substantial transplant-related
mortality, HSCT should currently be considered for care-
fully selected patients before severe organ damage has
occurred. It will be critical to optimize this treatment for
MNGIE in the future until other therapeutic approaches for
enzyme replacement become established and more widely
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Table 3 Complications and outcome
Patient aGvHD
grading
cGvHD
grading
Gastrointestinal function Peripheral neuropathy Last follow-up
(days after HSCT)
survival status
Cause of death
1 II 0 Improved Improved. Pre-transplant dif-
ficulties in walking and
climbing stairs, both nor-
malized at last follow-up.
2535 + , alive n.a.
2 0 0 Worsening of GI dysmotility No change 86 After graft failure progessive
MNGIE-related complica-
tions with septicaemia
3 0 0 Improved. Less diarrhea and
pseudo-obstruction;
stopped TPN
Dysaesthesias improved;
tendon reflexes returned
2450 + , alive n.a.
4 0 0 Worsened Worsened 281 After graft failure progres-
sive MNGIE-related com-
plications with liver and
pancreatic failure
5 0a 0a n.d. n.d. 331c Transplant-related toxicity:
alveolar haemorrhage,
infection
IVb -b 40
6 0 0 Improved. Less abdominal
pain but only able to have
minimal oral intake. TPN
ongoing
Improved 1196 Central line infection (need
for ongoing parenteral
nutrition due to
MNGIE-related gastro-
intestinal disorder)
Crawls, but unable to walk
7 0a 0a Improved Improved 473c n.a.
Ib Moderateb 1285 + , alive
8 0a 0a n.d. n.d. 247c Transplant-related toxicity:
multiorgan failure,
infection
0b -b 56
9 II Mild Improved, intermittent self-
limiting gastroparesis
Improved 1598 + , alive n.a.
10 I 0 n.a. n.d. 84 MNGIE-related intestinal
perforation with
infection
11 0 0 Improved. Able to tolerate
low residue diet.
Abdominal pain still pre-
sent. TPN ongoing
Improved. Pretransplant:
bed-bound, walks now un-
aided around the room
and mobilizes with a
gutter frame. Regained
movement in wrists,
thumbs and ankles,
increased power in
elbows and knees, increase
in sensory level
947 + , alive n.a.
12 0 0 Improved. Normalization of
GI symptoms
Improved 815 + , alive n.a.
Muscle strength improved
13 I - Worsened. Gastroparesis with
need for gastrostomy, spon-
taneous small bowel perfor-
ation with need for surgery
n.d. 150 MNGIE-related intestinal
perforation with postsur-
gical infectious
complications
14 IV - n.a. n.d. 77 Transplant-related aGvHD
15 0 - n.a. n.d. 18 Transplant-related veno-
occlusive disease of the
liver with multiorgan fail-
ure (post-mortem diag-
nosis of liver cirrhosis)
16 III-IV Severe Vomiting/diarrhea, abdominal
cramps/pain started to im-
prove 6 months after
HSCT. Resumed partial
oral nutrition, but re-
mained TPN dependent
n.d. 453 Septic shock after intestinal
perforation. Transplant-
related GvHD.
17 0 Mild Abdominal discomfort
markedly improved, still
recurrent episodes of
pseudo-obstruction
n.d. 246 MNGIE-related intestinal
pseudo-obstruction,
septic shock
Oral nutrition significantly
improved but still on
TPN at last follow up
(continued)
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available (Torres-Torronteras et al., 2011; Bax et al.,
2013).
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